Alimera: Correction to Earlier Post

Rather than simply correcting my earlier post on Alimera, I will note the correction here AND correct via editing, the prior post.

In my original post on Alimera, I stated that the royalty due to PSDV was 20% of revenue. This is incorrect. The 20% royalty rate applies, essentially, to pre-tax profits earned from sale of Iluvien. Thus, it is essentially a split of operating profits rather than a royalty payment.

This actually makes a substantial difference when doing a "back-of-the-envelope" estimation of ALIM's potential profitability, since royalties are not coming right off the top, but from somewhere in the middle of the income stream.

Jonathan Hains/alexalekhine